Innovative peptide therapeutics targeting IL17RA to regulate inflammatory responses., PMID:40121226
Bidirectional interaction between IL and 17A/IL-17RA pathway dysregulation and α-synuclein in the pathogenesis of Parkinson's disease., PMID:39461385
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial., PMID:38954226
Serum IL-17A concentration and a IL17RA single nucleotide polymorphism contribute to the risk of autoimmune type 1 diabetes., PMID:35583128
Increased IL-23R+ Th Cells Population Exhibits Higher SLEDAI-2K Scores in Systemic Lupus Erythematosus Patients., PMID:34484186
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment., PMID:34201664
[IL-17A/lL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy]., PMID:33243748
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials., PMID:33106286
Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway., PMID:33045560
One-Year Pharmacovigilance Update of Brodalumab., PMID:32845586
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells., PMID:32723833
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis., PMID:32600737
Genetic polymorphism in IL17RA induces susceptibility to Toxoplasma gondii infection in Brazilian pregnant women., PMID:32598917
Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options., PMID:32537467
Long-term safety of brodalumab in Japanese patients with plaque psoriasis: An open-label extension study., PMID:32275086
The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer., PMID:32210079
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis., PMID:32207067
The safety of brodalumab for the treatment of psoriasis., PMID:32053396
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure., PMID:32012238
Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes., PMID:31900603
Cajanonic acid A regulates the ratio of Th17/Treg via inhibition of expression of IL-6 and TGF-β in insulin-resistant HepG2 cells., PMID:31729529
Serum biomarker analysis in patients with premature ovarian insufficiency., PMID:31629109
Treatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab., PMID:31603633
Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition., PMID:31502653
New Targeted Therapies for Uncontrolled Asthma., PMID:31076057
Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases., PMID:30786053
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis., PMID:30661290
Effects of interleukin-17A in nucleus pulposus cells and its small-molecule inhibitors for intervertebral disc disease., PMID:30207057
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
Role of IL-17A receptor blocking in melanocyte survival: A strategic intervention against vitiligo., PMID:30120811
Rheumatoid arthritis and periodontal disease: What are the similarities and differences?, PMID:29341486
Two cases of skin infection during psoriasis treatment with brodalumab., PMID:29083051
Brodalumab: the first anti-IL-17 receptor agent for psoriasis., PMID:28650001
Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases., PMID:27856660
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease., PMID:27481309
[Pharmacological profile and clinical efficacy of fully human anti-IL-17RA antibody Brodalumab (LUMICEF® Subcutaneous Injection 210 mg Syringe)]., PMID:27725569
Brodalumab for the treatment of psoriasis., PMID:27718760
IL17RA gene variants and anti-TNF response among psoriasis patients., PMID:27670766
Preparation and Activity Detection of A Novel Monoclonal Antibody to Human Interleukin-17RA., PMID:27594156
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide., PMID:27184415
MCPIP1 RNase Is Aberrantly Distributed in Psoriatic Epidermis and Rapidly Induced by IL-17A., PMID:27180111
Interleukin-17A Induces IL-1β Secretion From RPE Cells Via the NLRP3 Inflammasome., PMID:26830368
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis., PMID:25985813
Use of brodalumab for the treatment of psoriasis and psoriatic arthritis., PMID:25917624
IL-17 Enhances Chemotaxis of Primary Human B Cells during Asthma., PMID:25494178
IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application., PMID:25272188
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing., PMID:25145755
IL-17 antibodies gain momentum., PMID:24172318
Propionibacterium acnes Induces an IL-17 Response in Acne Vulgaris that Is Regulated by Vitamin A and Vitamin D., PMID:23924903
IL-17C and its receptor IL-17RA/IL-17RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer., PMID:23834281
For research use only. Not for human or drug use.
